Oxfam Media reaction to Johnson & Johnson and Novovax COVID-19 Vaccine Results

Published on

Short URL: https://www.oxfam.org.uk/mc/ozgpp8/

In response to Johnson & Johnson (JNJ)’s and Novovax release of Phase 3 Trial results of their respective COVID-19 vaccines, Niko Lusiani, Senior Advisor with Oxfam America, said:

“Today marks yet another hopeful achievement in the fight against the coronavirus. The speed that the virus is mutating is only reinforcing the need for mass-produced vaccines available to everyone, everywhere, as soon as possible.

“As a single-dose, lower-cost vaccine, with corporate commitments to ensure access to all countries, rich and poor alike, the JNJ vaccine candidate could provide just the boost the world needs to save lives and prevent people from falling even deeper into poverty and despair.

“But no one company alone can produce enough vaccines to bend the curve completely. That’s why every COVID-19 vaccine must be a People’s Vaccine: patent-free, mass produced, distributed fairly based on need, and made available free of charge, to everyone, everywhere.”

/Ends

For more information, or to arrange an interview, please contact: Sarah Dransfield on 07884 114825 / sdransfield@oxfam.org.uk or the Oxfam media unit on: +44 (0)7748 761999 / media.unit@oxfam.org.uk

Press contact

For comments, interviews, or information please contact Sarah Dransfield (Senior Press Officer):